Inhaled Corticosteroids Withdrawal in Severe Patients With Chronic Obstructive Pulmonary Disease: A Wisdom Decision?;Retirada de corticoesteroides inhalados en pacientes graves con enfermedad pulmonar obstructiva crónica: ¿es una propuesta razonable?

Archivos de Bronconeumologia

Volumn 51, Issue 2, 2015, Pages 57-58

  Rodriguez Roisin, Robert ^a,b   Arismendi, Ebymar ^b  

^a HOSPITAL CLÍNIC   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; BRONCHODILATING AGENT; FLUTICASONE; SALMETEROL;

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE SEVERITY; DRUG WITHDRAWAL; HUMAN; CLINICAL TRIAL (TOPIC); INHALATIONAL DRUG ADMINISTRATION; METHODOLOGY; MULTICENTER STUDY (TOPIC); PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; DISEASE EXACERBATION; DRUG EFFECT; DYSPNEA; FORCED EXPIRATORY VOLUME; HAZARD RATIO; HEALTH STATUS; LUNG FUNCTION; MAINTENANCE THERAPY; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; BRONCHODILATOR AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; MULTICENTER STUDIES AS TOPIC; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESEARCH DESIGN;

EID: 84921528832     PISSN: 03002896     EISSN: 15792129     Source Type: Journal    
DOI: 10.1016/j.arbr.2014.11.023     Document Type: Article

References (10)

1. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. Update 2014 [consultado 20 Oct 2014]. Disponible en:. http://www.goldcopd.org/.
2. National Institute for Health and Clinical Excellence. Chronic obstructive pulmonary disease [consultado 20 Oct 2014]. Disponible en:. http://www.nice.org.uk/nicemedia/live/13029/49397/49397.pdf.
3. Celli B.R., MacNee W. Standards for the diagnosis and treatment of patients with COPD: A summary of the ATS/ERS position paper. Eur Respir J. 2004, 23:932-946.
4. Miravitlles M., Soler-Cataluna J.J., Calle M., Molina J., Almagro P., Quintano J.A., et al. Spanish COPD Guidelines (GesEPOC): Pharmacological treatment of stable COPD. Spanish Society of Pulmonology and Thoracic Surgery. Arch Bronconeumol. 2012, 48:247-257.
5. Magnussen H., Disse B., Rodriguez-Roisin R., Kirsten A., Watz H., Tetzlaff K., et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med. 2014, 371:1285-1294.
6. Van der Valk P., Monninkhof E., van der Palen J., Zielhuis G., van Herwaarden C. Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: The COPE Study. Am J Respir Crit Care Med. 2002, 166:1358-1363.
7. Wouters E.F.M., Postma D.S., Fokkens B., Hop W.C.J., Prins J., Kuipers A.F., et al. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: A randomised controlled trial. Thorax. 2005, 60:480-487.
8. Kumar S.D., Brieva J.L., Danta I., Wanner A. Transient effect of inhaled fluticasone on airway mucosal blood flow in subjects with and without asthma. Am J Respir Crit Care Med. 2000, 161:918-921.
9. Reilly J.J. Stepping down therapy in COPD. N Engl J Med. 2014, 371:1340-1341.
10. Calverley P.M., Sanchez-Toril F., McIvor A., Teichmann P., Bredenbroeker D., Fabbri L.M. Effect of one year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007, 176:154-161.